Format

Send to

Choose Destination
Cancer Med. 2016 Aug;5(8):1917-46. doi: 10.1002/cam4.775. Epub 2016 Jun 10.

MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Author information

1
Division of Science and Mathematics, Cancer Research Laboratory, University of the District of Columbia, Washington, District of Columbia, 20008.
2
Groton School, Groton, Massachusetts, 01450.
3
Department of Neurology and Pathology, Georgetown University, Washington, District of Columbia, 20057.
4
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, 20057.
5
Division of Cancer Control and Population Sciences, National Cancer Institute (NCI), National Institutes of Health (NIH), Rockville, Maryland, 20850.

Abstract

Glioblastoma multiforme (GBM) is the most common and lethal cancer of the adult brain, remaining incurable with a median survival time of only 15 months. In an effort to identify new targets for GBM diagnostics and therapeutics, recent studies have focused on molecular phenotyping of GBM subtypes. This has resulted in mounting interest in microRNAs (miRNAs) due to their regulatory capacities in both normal development and in pathological conditions such as cancer. miRNAs have a wide range of targets, allowing them to modulate many pathways critical to cancer progression, including proliferation, cell death, metastasis, angiogenesis, and drug resistance. This review explores our current understanding of miRNAs that are differentially modulated and pathologically involved in GBM as well as the current state of miRNA-based therapeutics. As the role of miRNAs in GBM becomes more well understood and novel delivery methods are developed and optimized, miRNA-based therapies could provide a critical step forward in cancer treatment.

KEYWORDS:

cancer therapy; glioblastoma multiforme; microRNA

PMID:
27282910
PMCID:
PMC4971921
DOI:
10.1002/cam4.775
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center